Eli Lilly Gets CDSCO Panel Nod To Market Mirikizumab for ulcerative colitis in adults
New Delhi: Pharmaceutical major Eli Lilly has got marketing authorization from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) for Mirkizumab Injection 300mg/15mL solution in vial and 100mg/mL solution in Prefilled Syringe (PFS) indicated for the treatment of moderate to severe active ulcerative colitis in adult. This came after […]